Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Given SFDA Approval for Generic Antibiotic

publication date: May 14, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group received SFDA approval for a first-to-market generic Biapenem injection, an antibiotic that it will market under the brand name Anxin. Biapenem is a member of the carbenicillin family, and it will compete in the marketplace against brand-name drugs such as Tienam from Merck and Mepem from Sumitomo Pharmaceuticals. Carbenicillins are used in patients who have developed resistance to other antibiotics.  More details...

Stock Symbols: (NYSE: SCR) (NYSE: MRK)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Partner Events

Shanghai, China
November 1-3, 2016

Shanghai, China
October 18-19, 2016

Del Mar, USA
October 1st, 2016

Del Mar, USA
October 1st, 2016

>> More events...